文献速递类风湿关节炎脊柱关节炎其他结缔组织病

SARS-CoV-2封锁对炎症性风湿病患者免疫调节药物依从性的影响:德国三个月横断面研究

The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究评估了2020年3月16日至6月15日德国封锁期间炎症性风湿病(IRD)患者对免疫调节治疗的依从性。共收集4252份问卷,大多数患者(84%)继续治疗,仅3%报告终止治疗,且依从性与疾病类型、治疗类型及就诊机构无关。

要点

  • 84%的IRD患者疫情期间继续免疫调节治疗,仅3%终止治疗。
  • 治疗依从性与疾病类型、免疫调节治疗种类及就诊机构无关。
  • 年轻患者(<60岁)与老年患者停药频率相似。

核心结论

  • 大多数患者在疫情期间继续免疫调节治疗,三个月观察期内未观察到治疗行为的显著改变。

研究设计与样本

  • 2020年3月16日至6月15日德国横断面问卷调查,8家私人诊所和9个风湿科参与,共收集4252份问卷。

主要发现

  • 54%患者为类风湿关节炎,14%银屑病关节炎,10%强直性脊柱炎,12%结缔组织病,6%血管炎。
  • 84%患者报告继续免疫调节治疗,仅3%报告终止治疗。
  • 治疗终止与IRD类型、免疫调节治疗种类及治疗机构(私人诊所 vs 风湿科)无关。
  • 年轻患者(<60岁)与老年患者报告停药频率相似。

临床怎么用

  • 数据支持德国风湿病学会及时发布的建议被良好接收,疫情期间医患关系稳固。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the influence of the SARS-CoV-2 pandemic on the adherence of patients with inflammatory rheumatic diseases (IRD) to their immunomodulatory medication during the three-month lockdown in Germany. METHODS: From 16th March until 15th June 2020, IRD patients from private practices and rheumatology departments were asked to answer a questionnaire addressing their behaviour with respect to their immunomodulating therapy. Eight private practices and nine rheumatology departments that included rheumatology primary care centres and university hospitals participated. A total of 4252 questionnaires were collected and evaluated. RESULTS: The majority of patients (54%) were diagnosed with RA, followed by psoriatic arthritis (14%), ankylosing spondylitis (10%), connective tissue diseases (12%) and vasculitides (6%). Most of the patients (84%) reported to continue their immunomodulatory therapy. Termination of therapy was reported by only 3% of the patients. The results were independent from the type of IRD, the respective immunomodulatory therapy and by whom the patients were treated (private practices vs rheumatology departments). Younger patients (<60 years) reported just as often as older patients to discontinue their therapy. CONCLUSION: The data show that most of the patients continued their therapy in spite of the pandemic. A significant change in behaviour with regard to their immunomodulatory therapy was not observed during the three months of observation. The results support the idea that the immediate release of recommendations of the German Society of Rheumatology were well received, supporting the well-established physician-patient relationship in times of a crisis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hasseli R, Müller-Ladner U, Keil F, et al. The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany. Rheumatology (Oxford). 2021. PMID: 33704418. doi:10.1093/rheumatology/keab230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。